• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    AstraZeneca shares slump after Phase 3 lung cancer drug study

    By: MarketWatch
    AstraZeneca shares fell Monday after a late-stage study on a lung cancer drug disappointed investors.
    Related Stocks:
    Astrazeneca Plc ADR
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.